Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Third Rock launches Tango Therapeutics

by Michael McCoy
April 3, 2017 | A version of this story appeared in Volume 95, Issue 14

The venture capital firm Third Rock Ventures has launched the cancer drug company Tango Therapeutics with $55 million in series A funding. Based in Cambridge, Mass., Tango says it will use DNA sequencing and CRISPR-enabled target discovery to exploit vulnerabilities created by loss of tumor suppressor gene function, an effect it calls synthetic lethality. One of Tango’s scientific founders is Alan Ashworth, whose work in synthetic lethality led to the discovery of small-molecule PARP inhibitors for ovarian cancer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.